Evidence map›Paper›PMID 21172016›Full record

ArticleMolecular cancer2010

A critical role for lymphatic endothelial heparan sulfate in lymph node metastasis.

Xin Yin, Jadwiga Truty, Roger Lawrence, Scott C Johns, R Sathish Srinivasan, Tracy M Handel, Mark M Fuster

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Cancers · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Lymphatic Regulation of Cellular Trafficking.Journal of clinical & cellular immunology · 2014
    Article
  15. Article
  16. Article
  17. Article
  18. Dendritic cell interactions with lymphatic endothelium.Lymphatic research and biology · 2013
    Review
  19. Article
  20. Chemokine receptor oligomerization and allostery.Progress in molecular biology and translational science · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xin YinDepartment of Medicine, Division of Pulmonary and Critical Care, University of California San Diego, La Jolla, CA 92037 USA.
Jadwiga Truty
Roger Lawrence
Scott C Johns
R Sathish Srinivasan
Tracy M Handel
Mark M Fuster
University of California, San Diego · USVA San Diego Healthcare System · USSt. Jude Children's Research Hospital · US

Funding

Siglec Modulation of Inflammation in Humans and MiceP01HL057345 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VARKI, NISSI MARY · 1997 to 2012
$24.1M
Prox1 in Mammalian LymphangiogenesisR01HL073402 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI OLIVER, GUILLERMO C · 2003 to 2020
$7.3M
STRUCTURE OF MACROPHAGE CHEMOTACTIC ACTIVATING PROTEINSR01AI037113 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HANDEL, TRACY M · 1995 to 2015
$5.2M
NHLBI NIH HHS P01-HL57345-11NHLBI NIH HHS R01-HL073402NIAID NIH HHS R01 AI037113
6 · The paper itself

Abstract

backgroundLymph node metastasis constitutes a key event in tumor progression. The molecular control of this process is poorly understood. Heparan sulfate is a linear polysaccharide consisting of unique sulfate-modified disaccharide repeats that allow the glycan to bind a variety of proteins, including chemokines. While some chemokines may drive lymphatic trafficking of tumor cells, the functional and genetic importance of heparan sulfate as a possible mediator of chemokine actions in lymphatic metastasis has not been reported.

resultsWe applied a loss-of-function genetic approach employing lymphatic endothelial conditional mutations in heparan sulfate biosynthesis to study the effects on tumor-lymphatic trafficking and lymph node metastasis. Lymphatic endothelial deficiency in N-deacetylase/N-sulfotransferase-1 (Ndst1), a key enzyme involved in sulfating nascent heparan sulfate chains, resulted in altered lymph node metastasis in tumor-bearing gene targeted mice. This occurred in mice harboring either a pan-endothelial Ndst1 mutation or an inducible lymphatic-endothelial specific mutation in Ndst1. In addition to a marked reduction in tumor metastases to the regional lymph nodes in mutant mice, specific immuno-localization of CCL21, a heparin-binding chemokine known to regulate leukocyte and possibly tumor-cell traffic, showed a marked reduction in its ability to associate with tumor cells in mutant lymph nodes. In vitro modified chemotaxis studies targeting heparan sulfate biosynthesis in lymphatic endothelial cells revealed that heparan sulfate secreted by lymphatic endothelium is required for CCL21-dependent directional migration of murine as well as human lung carcinoma cells toward the targeted lymphatic endothelium. Lymphatic heparan sulfate was also required for binding of CCL21 to its receptor CCR7 on tumor cells as well as the activation of migration signaling pathways in tumor cells exposed to lymphatic conditioned medium. Finally, lymphatic cell-surface heparan sulfate facilitated receptor-dependent binding and concentration of CCL21 on the lymphatic endothelium, thereby serving as a mechanism to generate lymphatic chemokine gradients.

conclusionsThis work demonstrates the genetic importance of host lymphatic heparan sulfate in mediating chemokine dependent tumor-cell traffic in the lymphatic microenvironment. The impact on chemokine dependent lymphatic metastasis may guide novel therapeutic strategies.

Indexed as

AnimalsBlotting, WesternCell Line, TumorCell MovementCells, CulturedChemokine CCL21Chromatography, AffinityCulture Media, ConditionedEndothelial CellsEnzyme-Linked Immunosorbent AssayFluorescent Antibody TechniqueHeparan SulfateHumansImmunohistochemistryLymphatic MetastasisMiceChemokine CCL21Culture Media, ConditionedHeparan Sulfateheparitin sulfotransferaseSulfotransferases

Identifiers

PMID21172016
PMCPMC3019167
OpenAlexW2171007477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.